IXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern
December 22, 2021 at 06:18 am EST
Share
iXensor Co., Ltd. declared that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies. In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control. Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.
IXENSOR CO., LTD. is a Taiwan-based company mainly engaged in the development of innovative application platform for intelligent mobile devices combined with cloud computing management physiological parameters. The Company's innovative technology platform can be used to measure biochemical parameters such as luteinizing hormone, blood sugar, glycated hemoglobin, total cholesterol, high-density cholesterol, triglycerides, myocardial infarction enzymes, and other immune response parameters, such as female hormone cycle changes, infectious diseases and others. The Company's products include PixoTest Blood Glucose Monitoring System, ovulation detection system and others.